GLP-2(T)

Tirzepatide is a dual GIP/GLP-1 receptor co-agonist built on a GIP peptide backbone with strategic modifications enabling balanced, high-affinity engagement of both incretin receptors — a mechanistic differentiation from pure GLP-1 agonists. Its simultaneous activation of GIPR and GLP-1R produces synergistic improvements in insulin secretion, glucagon suppression, gastric emptying, and satiety signaling, with preclinical and Phase 3 data demonstrating up to 22.5% mean body weight reduction at 72 weeks — outcomes that exceeded those observed with GLP-1 monotherapy in head-to-head models.

Beyond weight and glycemic control, tirzepatide research has revealed significant benefits in lipid metabolism, blood pressure, hepatic fat reduction, and insulin sensitivity, supporting its investigation across obesity, type 2 diabetes, MASH, and cardiovascular disease research models.

Specifications:

• Purity: ≥99% (HPLC verified)
• Form: Lyophilized powder
• Storage: −20°C

For Research Use Only.